Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03541564 · ClinicalTrials.gov registry record · Phase 1
An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects
A Phase 1 study of Healthy Participants and Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT03541564: Completed Phase 1 study of Healthy Participants and Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.
NCT03541564 is a Phase 1 study of Healthy Participants and Systemic Lupus Erythematosus that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 84 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (29% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03541564, a Phase 1 study of Healthy Participants and Systemic Lupus Erythematosus, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to investigate the experimental medication BMS-986165 in healthy participants in order to study the effects it has on electrocardiogram results.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Moxifloxacin
- DRUG BMS-986165
Study Locations (1)
Kansas
- PRA Health Sciences - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2018-09-04 |
| Phase | Phase 1 |
What the finished NCT03541564 record still lists
NCT03541564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (29% higher).
The record links to 2 conditions, with Healthy Participants appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03541564 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT03541564 about?
NCT03541564 is a clinical study titled "An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects". This is a study to investigate the experimental medication BMS-986165 in healthy participants in order to study the effects it has on electrocardiogram results.
What is the current status of trial NCT03541564?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2018-05-30. Estimated completion is 2018-09-04.
What conditions does trial NCT03541564 study?
This clinical trial studies the following conditions: Healthy Participants, Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT03541564?
The interventions under investigation include: Placebo (OTHER), Moxifloxacin (DRUG), BMS-986165 (DRUG).
Who is sponsoring clinical trial NCT03541564?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03541564 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03541564's enrollment target sits among peer trials
84 30th of 119 higher than 89 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI